

Substitute for form 1449A/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/993,647
		Filing Date	November 29, 2001
		First Named Inventor	Bernd Riedl et al.
		Group Art Unit	1624
Examiner Name	Deepak R. RAO		
Sheet	1 of 1	Attorney Docket Number	BAYER-0018-A

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	T-FI	CL	38688		Ciba-Geigy AG	06-04-1993	
	T-II	DE	487014	C1	I.G. Farbenindustrie Akt.-Ges.	11-14-1929	
	T-IB	DE	523437	C1	I.G. Farbenindustrie Akt.-Ges.	04-02-1931	

OTHER – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	T-P3a	Arzneimitteltherapie, "Sorafenib" October 6, 2006, Auflage 18498, 7 pages <i>English translation</i>		
	T-P23	Foussard-Blanpin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system," Ann. Pharm. Fr. (1982), 40 (4), pp. 339-350 <i>English translation</i>		
	T-P49a	Garbe, "Auch ein Therapieplatz für Sorafenib?" Medical Special (2006) 2 pages <i>English translation</i>		
	T-P59a	Dehtling, J. "Große Onkologie-Pipeline" Medizinische Monatsschrift für Pharmazeuten, 2006, Auflage 12914, 2 pages <i>English translation</i>		
	T-P64c	Dreves, J., Die Medizinische Welt, 2006, pp. 1/5, 2/5, 3/5, 4/5, 5/5 <i>English translation</i>		
	T-P132b	Jungmayr, P., "Aktueller Stand der Krebstherapie," Deutsche Apotheker Zeitung, Sept 30, 2004, Auflage ca. 36.000 <i>English translation</i>		
	T-P139	Kempter et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen," Pädagogische Hochschule, Eingegangen am 1.7.1982, Vol. 27, Issue 1, 101-120 (1983) <i>English translation</i>		
	T-P148	Kuefer et al., "Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway," Der Urologe, 2006, Vol. 45, No. 3, pp. 328, 330-335 <i>English translation</i>		
	T-P151	Kurik et al., "Optical Properties of Segmented Oligourethane with Azomethine Terminal Fragments," Polymer Science, series B, 1996, Vol. 38 pp. 2038-2041 <i>English translation</i>		
	T-P172a	Medinger et al., "Hemmung der Tumorangio-genese Neue Therapieoptionen in der Onkologie," Med Welt, 2006, 57, pp. 437-441 <i>English translation</i>		
	T-P172b	Med Report Deutschland, "Sorafenib zur Therapie des fortgeschrittenen Nierenzellkarzinoms zugelassen," (2006), 1 page <i>English translation</i>		
	T-P174	Michaelis, "Phenylharnstoff des 1-Phenyl-3-methyl-5-aminopyrazols," Justus Liebigs Ann. Chem. (JLACBF) 397, 1913, p. 143 <i>English translation</i>		
	T-P210b	Peters, H.D., "Sorafenib bei soliden Tumoren," Focus Onkologie, 2007, Auflage 12000, 6 pages <i>English translation</i>		
	T-P266a	Strumberg et al., "Sorafenib Neue Therapieoption in der Onkologie," Krankenhauspharmazie, 2007, Vol. 28, pp. 93-97, pages 1/5, 2/5, 3/5 and 4/5 <i>English translation</i>		
	T-P294a	Stofforz, "Die Krebsformel, die der Zufall fand," Frankfurter Allgemeine Sonntagszeitung, July 2, 2006, NR 26, pp. 68-69 <i>English translation</i>		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number (optional). <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*